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Purpose: Lymphocyte subset recovery is an important factor that determines the success of 
hematopoietic stem cell transplantation (HSCT). Temporal differences in the recovery of lymphocyte 
subsets and the factors influencing this recovery are important variables that affect a patient’s post-
transplant immune reconstitution, and therefore require investigation.
Methods: The time taken to achieve lymphocyte subset recovery and the factors influencing this 
recovery were investigated in 59 children who had undergone HSCT at the Department of Pediatrics, 
The Catholic University of Korea Seoul St. Mary’s Hospital, and who had an uneventful follow-up period 
of at least 1 year. Analyses were carried out at 3 and 12 months post-transplant. An additional study 
was performed 1 month post-transplant to evaluate natural killer (NK) cell recovery. The impact of pre- 
and post-transplant variables, including diagnosis of Epstein-Barr virus (EBV) DNAemia posttransplant, 
on lymphocyte recovery was evaluated.
Results: The lymphocyte subsets recovered in the following order: NK cells, cytotoxic T cells, B cells, 
and helper T cells. At 1 month post-transplant, acute graft-versus-host disease was found to contribute 
significantly to the delay of CD16
+/56
+ cell recovery. Younger patients showed delayed recovery of both 
CD3
+/CD8
+ and CD19
+ cells. EBV DNAemia had a deleterious impact on the recovery of both CD3
+ and 
CD3
+/CD4
+ lymphocytes at 1 year post-transplant.
Conclusion: In our pediatric allogeneic HSCT cohort, helper T cells were the last subset to recover. 
Younger age and EBV DNAemia had a negative impact on the post-transplant recovery of T cells and B 
cells.
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Introduction
Hematopoietic stem cell transplantation (HSCT) is now widely used for the treat­
ment of children with blood diseases. An important factor in the prognosis of the 
patient post­transplant is host immune reconstitution (IR) which, if delayed, may 
increase the risk of infection, disease recurrence and secondary malignancies after 
transplant
1). IR is affected by various treatment­related variables, such as the period 
of antibiotic use, routine administration of intravenous immunoglobulin (IVGV), and 
immunomodulatory treatment after transplant such as donor lymphocyte infusion. 
According past literature, IR occurs in the order of monocyte, granulocyte, macro­27 http://dx.doi.org/10.3345/kjp.2013.56.1.26
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phage, and natural killer (NK) cell, resulting in the restoration 
of a functional innate immune system. Recovery of the adap­
tive immune system, however, occurs over a considerably 
long  er period of time, with B cell restoration requiring at least 
six months, and T cell recovery often taking two years for 
completion
1).
Factors influencing IR at the time of transplant include pa­
tient age, donor type, stem cell source, and method of T cell 
depletion, while prevention and treatment of graft­versus­host 
disease (GVHD) are significant factors influencing IR after 
transplant
2).
According to a recent Korean study on pediatric recipients 
of allogeneic HSCT, NK cells and cytotoxic T cells were ra­
pidly restored after HSCT, with 92% and 76% of patients, 
respectively showing recovery at 3 months post­transplant. 
However, IR was slower for helper T cells and B cells which 
showed recovery in 85% and 69% of patients, respectively 
at 12 months post­transplant
3). Important results that derive 
from this study are the negative effects of certain conditioning 
regimens, including the use of total body irradiation (TBI) 
and antithymocyte globulin (ATG), cord blood as the cell 
source, and diagnosis of chronic GVHD, on lymphocyte re­
constitution.
Despite this and other previous reports on IR
4,5), studies on 
IR in pediatric recipients of allogeneic HSCT are few. Also, an 
important factor which has not yet received full analysis as a 
possible modulator of IR is post­transplant Epstein­Barr virus 
(EBV) infection.
In this study, we evaluated the recovery of each lymphocyte 
subset in 59 recipients of allogeneic HSCT at our institution. 
In addition to the impact of well­established variables such 
as patient age, donor type, acute and chronic GVHD on IR, 
we also analyzed EBV infection for possible effects on lym­
phocyte recovery.
Materials and methods
1. Patient cohort
From January 2009 to December 2010, 90 patients received 
allogeneic HSCT at the Department of Pediatrics, The Catholic 
University of Korea Seoul St. Mary’s Hospital. Out of this 
initial cohort, the following exclusions were made: 14 patients 
who relapsed within 1 year of transplant, 8 patients who died 
of transplant­related mortality within 1 year, 2 patients who 
experienced graft failure, and 7 patients with incomplete 
records concerning lymphocyte subset recovery. The final 
study cohort included 59 patients, the major characteristics of 
whom are summarized in Table 1.
2. Transplant method 
For infection prophylaxis, oral acyclovir was given from 
the start of conditioning to day 42, and oral trimethoprim­
sulfamethoxazole was given from the start of conditioning to 
day ­3, and from neutrophil engraftment to at least 6 months 
after transplant. Granulocyte­colony stimulating factor was 
given from day 5 to the time when the absolute neutrophil 
count surpassed 3.0×10
9/L. For antifungal prophylaxis, we 
administered intravenous (IV) micafungin (1 mg/kg/day) from 
the start of conditioning to neutrophil engraftment, followed 
by oral fluconazole for at least 2 months.
GVHD prophylaxis consisted of IV cyclosporine from day 
­1 and mini­dose methotrexate (5 mg/m
2) given at days 1, 3, 6, 
and 11. 
After transplant, EBV DNA titers were evaluated at fort­
nightly intervals for up till 3 months post­transplant using a 
real­time quantitative method. Rituximab was admini  stered 
only with diagnosis of post­transplantation lymphoproliferative 
Table 1. Characteristics of patient cohort (n=59)
Characteristic Value
Age at HSCT (yr) 6.9 (0.3–13.5)
Sex
Male 38 (64.4)
Female 21 (35.6)
Diagnosis
  ALL 6 (10.2)
  AML 15 (25.4)
  CML 2 (3.4)
  Fanconi anemia 4 (6.8)
  HLH 4 (6.8)
  JMML 2 (3.4)
  Lymphoma 2 (3.4)
  MDS 4 (6.8)
  SAA 20 (33.9)
Conditioning regimen
  With TBI 8 (13.5)
  With ATG 47 (79.6)
Type of donor
  Matched related 26 (44.1)
  Unrelated 33 (55.9)
Stem cell source
  Bone marrow 6 (10.2)
  Peripheral blood stem cell 53 (89.8)
Values are presented as median (range) or number (%).
HSCT, hematopoietic stem cell transplantation; ALL, acute lymphoblastic 
leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; 
HLH, hemophagocytic lymphohistiocytosis; JMML, juvenile myelomonocytic 
leukemia; MDS, myelodysplastic syndrome; SAA, severe aplastic anemia; TBI, 
total body irradiation; ATG, antithymocyte globulin.http://dx.doi.org/10.3345/kjp.2013.56.1.26
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disease (PTLD).
3. Immunophenotypic studies
Bone marrow examination and peripheral blood lymphocyte 
subset analysis were done at intervals of 1, 3, 6, 9, and 12 
months after HSCT. 
With peripheral blood, CD3
+, CD3
+/CD4
+, CD3
+/CD8
+, CD19
+ 
and CD16
+/CD56
+, the antigens of T cell, B cell, and NK cell, 
were analyzed through fluorescence­activated cell sorter 
system, and the absolute values of each subset were calculated 
using the percentage of each lymphocyte subset and the 
absolute lymphocyte counts (ALCs). 
The normal value of each lymphocyte subset varies ac­
cording to age
1). In this study, the normal values for each lym­
phocyte subset, as outlined in a previously published paper, 
were used
2).
4. Study endpoints
The main study endpoints were as follows; first, we aimed 
to identify the number of patients with lymphocyte sub­
set recovery, defined as the 25th percentile of normal val  ue. 
Second, we analyzed for factors that may impact the re  covery 
of each lymphocyte subset, including patient age, donor type, 
stem cell source, the use of either TBI or ATG in conditioning, 
diagnosis of acute or chronic GVHD, and EBV DNAemia. 
For this second analysis, both the 25th and 75th percentile 
of normal values were used. EBV DNAemia was defined as 
having a positive value when more than 500 copies were 
detected per 1 mL by real­time quantitative polymerase chain 
reaction. All analyses were done for 3 and 12 months post­
transplant. In addition, analyses for NK cell recovery and 
risk factors for NK cell recovery were done at 1 month post­
transplant.
5. Statistical analysis
Logistic regression analysis was performed to determine 
whether the pre­ and post­transplant independent variables 
had a significant impact on recovery of each lymphocyte sub­
set. Factors with a P value<0.05 in univariate analysis were 
entered into a multivariate study. Statistical analysis was done 
using the SAS ver. 8 (SAS Institute Inc., Cary, NC, USA). The P 
value was considered significant when <0.05.
Results
1. Recovery of each lymphocyte subset to normal value
With regards to ALC, 34 patients (57%) in the overall cohort 
showed recovery at 12 months post­transplant (Table 2). CD3
+/
CD4
+ was the slowest lymphocyte subset to show recovery, 
with 14 patients (23%) showing recovery at 12 months post­
transplant, followed by CD19
+ which showed recovery in 28 
patients (47%).
With regards to CD3
+/CD8
+ lymphocyte, 26 patients (46%) 
showed recovery at 3 months post­transplant, the number 
in  creasing to 41 patients (70%) at 12 months. Twenty­eight 
pa  tients (47%) showed recovery of CD16
+/CD56
+ lymphocytes 
at 1 month post­transplant, and the number increased to 40 
patients (67%) at 12 months.
2. Factors influencing the recovery of lymphocyte subset (Table 3)
1) Total lymphocyte count recovery
The use of ATG in conditioning significantly decreased the 
percentage of patients with total lymphocyte count recovery 
(25th percentile reference) at 12 months post­transplant (P= 
0.035). However, none of the other factors proved significant at 
any of the time points evaluated.
2) CD16
+/CD56
+ subset recovery
With regards to CD16
+/CD56
+ cell recovery (75th percentile 
reference) at 1 month post­transplant, patient age, treatment 
with TBI in conditioning, and diagnosis of acute GVHD proved 
to be important in univariate study. However, in multivariate 
analysis, the presence of acute GVHD was most significant in 
terms of delaying CD16
+/CD56
+ cell recovery (odds ratio [OR], 
Table 2. Summary of lymphocyte reconstitution in the overall cohort (n=59)
Lymphocyte subgroup
Post-HSCT (3 mo) Post-HSCT (12 mo)
Absolute count, 
median (range), (/mm
2)
No. of patients with 
normal values (%)
Absolute count, 
median (range), (/mm
2)
No. of patients with 
normal values (%)
Total 1,205 (358–3,990) 10 (16) 2,599 (1,076–9,963) 34 (57)
CD3
+ 749 (40–3,084) 13 (22) 1,765 (694–6,446) 37 (62)
CD3
+/CD4
+ 166 (2–865) 0 (0) 566 (188–1,664) 14 (23)
CD3
+/CD8
+ 488 (3–2,230) 26 (46) 875 (331–5,041) 41 (70)
CD16
+/CD56
+ 226 (49–1,350) 32 (54) 286 (60–2,112) 40 (67)
CD19
+ 89 (0–1,416) 6 (10) 417 (40–1,612) 28 (47)
HSCT, hematopoietic stem cell transplantation; CD, cluster of differentiation.29 http://dx.doi.org/10.3345/kjp.2013.56.1.26
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24.3; 95% confidence interval [CI], 1.95 to 4,118.36; P=0.0076). 
In addition, diagnosis of EBV DNAemia, and unrelated trans­
plant significantly delayed CD16
+/CD56
+ cell recovery at 3 
months post­transplant for the 25th and 75th percentile re­
ference levels respectively, on univariate analysis. 
3) CD3
+ subset recovery
At 12 months post­transplant, both EBV DNAemia and 
un  related transplant significantly delayed overall CD3
+ lym­
phocyte recovery (25th percentile reference). However, in 
multi  variate study, only EBV DNAemia proved to be have 
significant impact (OR, 3.56; 95% CI, 1.16 to 10.87; P=0.026).
4) CD3
+/CD8
+ subset recovery
At 12 months post­transplant, younger age (<10 years old), 
and the presence of either acute or chronic GVHD significantly 
delayed CD3
+/CD8
+ cell recovery (75th percentile reference). 
However, in multivariate analysis, only younger age had a 
significant impact on cytotoxic T cell recovery (OR, 3.72; 95% 
CI, 1.17 to 11.76; P=0.026).
5) CD3
+/CD4
+ subset recovery
Diagnosis of EBV DNAemia significantly decreased CD3
+/
CD4
+ recovery at 12 months post­transplant (P=0.033) (25th 
percentile reference). However, none of the other variables had 
a major impact on helper T cell subset recovery.
6) CD19
+ subset recovery
Both younger patient age and EBV DNAemia had negative 
effects on CD19
+ recovery at 12 months post­transplant (25th 
percentile reference). In multivariate study, however, younger 
patient age was most significant in terms of delaying B cell 
recovery (OR, 3.86; 95% CI, 1.15 to 12.99; P=0.029).
Table 3. Factors influencing lymphocyte subset reconstitution after HSCT (1, 3, and 12 months post-transplant)
Post-HSCT 
(1 mo, 75P)
Post-HSC
(3 mo, 25P)
Post-HSCT 
(3 mo, 75P)
Post-HSCT 
(12 mo, 25P)
Post-HSCT 
(12 mo, 75P)
CD16
+/
CD56
+
P 
value
CD3
+/
CD8
+
P 
value
CD16
+/
CD56
+
P 
value
CD16
+/
CD56
+
P 
value
ALC
P 
value
CD3
+ P 
value
CD3
+/
CD4
+
P 
value
CD19
+ P 
va lue
CD3
+ P 
value
CD3
+/
CD8
+
P 
value
CD16
+/
CD56
+
P 
value
Age (yr) 0.027 0.002 NS NS 0.058 NS NS 0.026 NS 0.024 NS
  <10 4/36 15/25 24/16 17/23 19/21 24/16 10/30 15/25 10/30 11/29 9/31
  ≥10 7/12 7/12 8/11 5/14 14/5 13/6 3/16 13/6 7/12 11/8 8/11
Donor type NS NS NS 0.027 0.058 0.027 NS 0.054 NS NS 0.086
  Related 7/19 9/17 16/10 10/16 15/11 16/10 8/18 16/10 9/17 11/15 8/18
  Unrelated 4/19 13/20 16/17 12/21 18/15 21/12 5/28 12/21 8/25 11/22 9/24
Source NS 0.074 NS NS NS NS NS NS NS NS NS
  BM 0/6 0/6 3/3 3/3 2/4 4/2 1/5 2/4 0/6 1/5 0/6
  PB 11/42 20/31 29/24 19/34 31/22 33/20 12/41 26/27 17/36 21/32 17/36
TBI 0.032 NS NS NS NS NS NS NS NS NS NS
  Yes 4/4 2/6 4/4 2/6 5/3 4/4 1/7 4/4 2/6 3/5 3/5
  No 7/44 20/31 28/23 20/31 28/23 33/18 12/39 24/27 15/36 19/32 14/37
ATG NS NS NS NS 0.035 NS NS NS NS NS NS
  Yes 8/39 18/29 24/23 18/29 26/21 31/16 10/37 20/27 14/33 17/30 13/34
  No 3/9 4/8 8/4 4/8 7/5 6/6 3/9 8/4 3/9 5/7 4/8
aGVHD 0.013 NS NS NS
  Yes 0/18 9/9 12/6 9/9
  No 11/30 13/28 20/21 13/28
aGVHD (≥grade II) NS NS NS 0.094 0.013 0.028 0.013
  Yes 9/9 10/8 2/16 8/10 5/13 7/11 5/13
  No 24/17 27/14 11/30 20/21 12/29 15/26 12/29
cGVHD NS 0.019 0.060 0.010 NS NS NS NS 0.019 NS
  Yes 2/12 5/9 8/6 8/6 7/7 2/12 6/8 3/11 5/9 3/11
  No 9/36 17/28 24/21 25/20 30/15 11/34 22/23 14/31 17/28 14/31
EBV DNAemia 0.074 NS 0.020 NS 0.024 0.033 0.049 NS NS 0.041
  Yes 5/24 10/19 16/13 14/15 14/15 3/26 10/19 7/22 10/19 8/21
  No 6/24 12/18 16/14 19/11 23/7 10/20 18/12 10/20 12/18 9/21
Data represented as number of patients with subset recovery within specified category/number of patients within specified category.
HSCT, hematopoietic stem cell transplantation; 75P, 75th percentile reference; 25P, 25th percentile reference; CD, cluster of differentiation; ALC, absolute 
lymphocyte count; BM, bone marrow; PB, peripheral blood; TBI, total body irradiation; ATG, anti-thymocyte globulin; aGVHD, acute graft versus host disease; cGVHD, 
chronic GVHD; EBV, Epstein-Barr virus; NS, not significant.http://dx.doi.org/10.3345/kjp.2013.56.1.26
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Discussion
Previous studies have shown that among lymphocyte sub­
sets, NK cells are the first to recover to normal levels after 
allogeneic HSCT. The recovery of T cells and B cells is much 
slower, and amongst T cells, cytotoxic T cells seem to show 
faster reconstitution than helper T cells
3).
The timing of B cell and T cell recovery has been a matter 
of controversy, with several previous studies concluding that 
the B cell recovered faster than the helper T cell, allowing 
the B cell to stimulate the thymus for T cell maturation and 
differentiation
1). The results from our study also support the 
view that B cell recovery precedes helper T cell recovery, 
allowing for sequential lymphocyte maturation. 
Although the NK cell is known to repopulate rapidly, only 
47% of the cohort showed normal levels by 1 month since 
transplant. Factors contributing to delayed early recovery 
of NK cells were younger patient age, the use of TBI in the 
conditioning regimen, and previous diagnosis of acute GVHD, 
with the last factor proving most significant in multivariate 
study.
Several important points can be made regarding factors that 
influence the recovery of each lymphocyte subset.
Although patient age has been reported to be an important 
factor, the age threshold with which the overall cohort has 
been divided, has varied from 10 to 16 years old
2,4). Reports 
on the impact of patient age have also been conflicting. Some 
researchers have suggested that lymphocyte recovery occurs 
much faster in older patients
2), while others have shown evi­
dence that recovery is faster in the younger age group
4). In our 
study, patients in the younger age group showed a significantly 
lower likelihood of both cytotoxic T cell and B cell recovery 
at 12 months post­transplant in multivariate analysis. One 
hypothesis for this result is that younger children may have 
less mature lymphoid organs that are more prone to damage 
from the HSCT conditioning regimen.
Previous reports have shown that, although there is no dif­
fer  ence in recovery of the innate immune system, related and 
unrelated transplants have shown discrepancies with regards 
to recovery of antigen­specific cellular immunity
6). In our 
study, the effect of donor type in post­transplant IR was not 
significant in multivariate study, although univariate effects 
of delayed CD16
+/CD56
+ and CD3
+ cell recovery were noted.
Past studies have shown a faster rate of CD3
+/CD4
+ and 
CD3
+/CD8
+ lymphocyte recovery in recipients of peripheral 
blood stem cell transplantation, compared to bone marrow 
transplantation
7). Our study did not show an advantage for 
either cell source with regards to IR, consistent with a recent 
domestic report on immune recovery
3). 
The effect of ATG administered as part of the conditioning 
regimen on IR is a matter of controversy, with at least 1 study 
concluding that ATG has no significant effect on immu­
nological recovery
8). In our study, the use of ATG had a signi  ­
ficantly detrimental effect on the recovery of ALC, as evi­
denced at 1 year post­transplant.
The possible role of GVHD in IR has been studied consi­
derably, with published data suggesting that acute GVHD 
and subsequent treatment may delay the recovery of CD3
+/
CD4
+ lymphocytes
9). GVHD is known to deter the activities 
of the thymus, and suppress both CD3
+/CD4
+ and CD3
+/CD8
+ 
lymphocytes, as well as CD19
+ lymphocytes
5). Our analysis 
showed that acute GVHD had a significant role in the delayed 
recovery of innate immunity, as represented by the CD16
+/
CD56
+ subset in the early period after transplant. In contrast, 
diagnosis of chronic GVHD did not have a significant impact 
in multivariate analysis.
Relatively little is known of the impact of EBV infection 
on the recovery of specific lymphocyte subsets. Past studies 
have shown that lymphocyte subset recovery was accelerated 
with cytomegalovirus infection
5), and that EBV specific T 
lymphocytes increased with EBV infection
10). The entity of 
PTLD would indicate that B cell lymphocyte proliferation is 
increased by EBV infection to the extent of gaining malignant 
potential
11­13), and another study found that early infection by 
EBV or adenovirus delayed immune reconstruction because 
such early infections are linked to pathogenesis of chronic 
GVHD
14). In our study, we found that EBV infection, as dia­
gnosed by EBV DNA titers, significantly delayed recovery 
of CD3
+ cells in multivariate study, was the only important 
factor in analysis of CD3
+/CD4
+ cell recovery, and was also 
significant in delayed recovery of CD19
+ cells, although not 
in multivariate study. Whether EBV infection was actually 
responsible for delayed CD3
+ recovery is problematic, as past 
literature supports the converse situation; CD3
+/CD4
+ cells and 
CD3
+/CD8
+ cells are known to prevent EBV infection
15­17), and 
in vivo T cell depletion, as was done for our unrelated donor 
transplant recipients, may have played a role in subsequent 
EBV infection. However, considering EBV infection was the 
independent factor and CD3
+ recovery status the outcome, or 
dependent factor, in our regression analyses, our data also 
point to the possibility of delayed CD3
+ recovery by EBV 
infection.
In conclusion, the lymphocyte subsets in our study recovered 
in the following order: CD16
+/CD56
+, CD3
+/8
+, CD19, and 
CD3
+/4
+. In multivariate study, acute GVHD, EBV infection, 
and younger patient age had major effects on the delayed 
recovery of CD16
+/56
+, CD3
+, and CD19
+ cells, respectively. The 
results from our pediatric cohort should contribute to a greater 
understanding of IR after allogeneic HSCT in children, and 
may provide the basis for larger scale studies of the role of both 31 http://dx.doi.org/10.3345/kjp.2013.56.1.26
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debated and unrecognized factors such as patient age and EBV 
infection, in post­transplant immune recovery. 
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